Profile data is unavailable for this security.
About the company
RaQualia Pharma Inc. is a Japan-based company engaged in the research and development of pharmaceutical products. The Company is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The Company is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.
- Revenue in JPY (TTM)2.30bn
- Net income in JPY-673.00m
- Incorporated2008
- Employees67.00
- LocationRaQualia Pharma Inc8F, Daiwa Meieki Bldg.1-21-19, Meieki-MinamiNakamura-kuNAGOYA-SHI 450-0003JapanJPN
- Phone+81 524466100
- Fax+81 525650700
- Websitehttps://www.raqualia.com/
More ▼
Mergers & acquisitions
| Acquired company | 4579:TYO since announced | Transaction value |
|---|---|---|
| FIMECS Inc | -26.90% | 29.84m |
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liberta Co Ltd | 8.32bn | 1.20m | 6.21bn | 118.00 | 6,469.22 | 4.05 | 46.70 | 0.7463 | 0.1594 | 0.1594 | 1,394.93 | 254.52 | 1.36 | 2.90 | 7.11 | 70,479,750.00 | 0.0196 | 3.75 | 0.0411 | 6.42 | 37.56 | 41.81 | 0.0144 | 2.37 | 0.7485 | 3.19 | 0.7064 | 35.67 | 6.77 | 9.76 | -2.77 | -12.85 | 23.12 | -- |
| NIPPON CHEMIPHAR CO., LTD. | 31.54bn | -255.00m | 6.45bn | 887.00 | -- | 0.2945 | 5.72 | 0.2046 | -70.67 | -70.67 | 8,739.80 | 5,141.74 | 0.613 | 2.04 | 2.95 | 35,554,680.00 | -0.4976 | 0.7482 | -0.6958 | 1.08 | 26.07 | 30.99 | -0.8117 | 1.13 | 1.52 | -0.7059 | 0.5041 | 50.73 | -2.57 | -2.10 | -153.10 | -- | 24.62 | -12.94 |
| COSMO BIO COMPANY, LIMITED | 9.87bn | 367.00m | 7.11bn | 155.00 | 18.68 | 0.767 | 13.64 | 0.7199 | 62.89 | 62.89 | 1,691.08 | 1,531.97 | 0.8932 | 5.95 | 3.96 | 63,690,320.00 | 3.49 | 5.62 | 4.06 | 6.72 | 32.98 | 37.40 | 3.91 | 6.23 | 6.67 | -- | 0.0021 | 33.53 | -2.23 | 5.16 | -14.51 | 11.20 | -8.03 | 16.47 |
| Wakamoto Pharmaceutical Co Ltd | 7.93bn | 190.01m | 8.29bn | 274.00 | 43.47 | 0.6914 | 13.63 | 1.05 | 5.47 | 5.47 | 228.52 | 344.22 | 0.5106 | 2.00 | 3.29 | 28,945,390.00 | 1.22 | -2.28 | 1.39 | -2.64 | 47.52 | 51.00 | 2.40 | -3.97 | 3.48 | -- | 0.0083 | -- | -10.65 | -6.35 | -21.19 | -- | 4.93 | -- |
| K Pharma Inc | 0.00 | -680.95m | 8.31bn | 15.00 | -- | 3.10 | -- | -- | -58.58 | -58.58 | 0.00 | 230.79 | 0.00 | 0.00 | -- | 0.00 | -27.16 | -- | -29.66 | -- | -- | -- | -- | -- | 34.85 | -- | 0.00 | -- | -- | -- | 166.34 | -- | -- | -- |
| Kohjin Bio Co Ltd | -100.00bn | -100.00bn | 8.92bn | 159.00 | -- | 1.69 | -- | -- | -- | -- | -- | 1,032.83 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.73 | -- | 0.2846 | -- | 0.5715 | -- | -53.61 | -- | -- | -- |
| Solasia Pharma KK | 95.00m | -1.21bn | 9.60bn | 24.00 | -- | 4.34 | -- | 101.05 | -6.62 | -6.62 | 0.51 | 10.14 | 0.0408 | 0.5763 | 0.7724 | 3,958,333.00 | -52.22 | -48.57 | -57.64 | -58.83 | 10.53 | 71.01 | -1,278.95 | -300.89 | 7.39 | -- | 0.016 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
| Perseus Proteomics Inc | 108.86m | -966.41m | 9.77bn | 25.00 | -- | 5.32 | -- | 89.78 | -75.66 | -75.66 | 8.50 | 124.71 | 0.0521 | 2.76 | 9.44 | 4,354,200.00 | -46.23 | -41.34 | -48.96 | -43.43 | 89.12 | 91.72 | -887.79 | -891.26 | 15.69 | -101.42 | 0.00 | -- | 6.58 | -18.31 | -40.34 | -- | 60.30 | -- |
| RaQualia Pharma Inc | 2.30bn | -673.00m | 10.08bn | 67.00 | -- | 1.79 | -- | 4.39 | -31.12 | -31.12 | 106.28 | 261.02 | 0.2652 | 3.82 | 2.89 | 34,300,980.00 | -7.77 | 2.13 | -8.56 | 2.26 | 84.78 | 88.49 | -29.28 | 5.32 | 3.55 | -- | 0.3972 | 0.00 | -34.85 | 20.62 | -144.74 | -- | 0.0967 | -- |
| ReproCell Inc | 2.60bn | -196.44m | 10.94bn | 96.00 | -- | 1.25 | -- | 4.21 | -2.21 | -2.21 | 29.29 | 92.79 | 0.2916 | 5.05 | 7.43 | 27,084,280.00 | -2.20 | -7.35 | -2.37 | -8.00 | 51.10 | 39.83 | -7.55 | -27.16 | 8.97 | -- | 0.00 | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
| Symbio Pharmaceuticals Ltd | 3.07bn | -4.02bn | 11.11bn | 109.00 | -- | 2.15 | -- | 3.62 | -92.13 | -92.13 | 70.03 | 112.55 | 0.4225 | 2.97 | 4.47 | 28,137,370.00 | -55.36 | -19.18 | -62.58 | -23.62 | 77.57 | 65.84 | -131.05 | -24.32 | 6.51 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
| Ohki Healthcare Holdings Co Ltd | 342.45bn | 1.87bn | 12.00bn | 632.00 | 6.26 | 0.3897 | 5.48 | 0.035 | 136.22 | 136.22 | 24,995.05 | 2,189.15 | 2.45 | 12.90 | 4.52 | 541,849,700.00 | 1.29 | 1.85 | 5.54 | 8.42 | 5.00 | 6.16 | 0.5268 | 0.7178 | 0.8641 | -- | 0.2547 | 13.92 | 9.92 | 5.30 | 1.28 | 1.51 | -5.34 | 5.92 |
Data as of Nov 22 2024. Currency figures normalised to RaQualia Pharma Inc's reporting currency: Japanese Yen JPY
0.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Simplex Asset Management Co., Ltd.as of 07 Nov 2024 | 103.40k | 0.48% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 18.30k | 0.09% |
| DFA Australia Ltd.as of 31 May 2023 | 1.72k | 0.01% |
| LGT Capital Partners AG (Investment Management)as of 31 May 2024 | 300.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
